Zanidatamab Plus Chemo ± Tislelizumab May Replace First-Line Standard of Care in HER2+ Gastroesophageal Adenocarcinoma | OncLive HERIZON-GEA-01 is the first phase 3 study to demonstrate a median PFS greater than 1 year, and a median OS greater than 2 years in metastatic GEA.

Zanidatamab Plus Chemo ± Tislelizumab May Replace First-Line Standard of Care in HER2+ Gastroesophageal Adenocarcinoma @ascocancer.bsky.social #GI26 #esocsm #oncology
www.onclive.com/view/zanidat...

Delving into the❓“Organ Preservation for Gastroesophageal Junction & Gastric Adenocarcinoma: Ready for Primetime?” w co-chairs Drs. Daniel Tandel Chang & Ugwuji Maduekwe @ #GI26. Case-based discussions w/ opposing views. 🔥 #esocsm meetings.asco.org/meetings/202...

A great opening session continues at #GI26 with “Oral Abstract Session A: Cancers of the Esophagus & Stomach” co-chaired by Dr. David Wang & Dr. Nathaniel Evans. #esocsm #stcsm
meetings.asco.org/meetings/202...

Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC | OncLive Tislelizumab plus induction chemotherapy and concurrent chemoradiation demonstrated efficacy worthy of further study in locally advanced ESCC.

Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC @myesmo.bsky.social #ESMO2025 #ESMO25 #esocsm #Oncology
www.onclive.com/view/tisleli...

The draft guideline update, #immunotherapy and targeted therapy for advanced gastroesophageal cancer, is now available for open comment.

Provide your feedback to us by September 24. #esocsm Learn more: brnw.ch/21wVG8d

Clinical Trial S2013

#ClinicalTrial S2013 #ICHECKIT follows patients taking #immunotherapy and chemotherapy drugs for #cancer, to learn who is at risk for serious side effects. To learn more about S2013, visit SWOG.org/S2013. Or call 1-800-4-Cancer and ask about S2013.
@swog.org
#esocsm #gicsm

Satri-Cel NDA Gets Go-Ahead From NMPA in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer The NMPA of China has accepted the new drug application for satricabtagene autoleucel in pretreated gastric/GEJ cancer.

Satri-Cel NDA Gets Go-Ahead From NMPA in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer #esocsm #oncology
www.onclive.com/view/satri-c...

Frontline Disitamab Vedotin Yields Responses in Gastric/GEJ Cancer With Various HER2 Expression Levels The addition of disitamab vedotin to toripalimab and trastuzumab and/or CAPOX led to favorable response rates in HER2-expressing gastric/GEJ cancer.

Frontline Disitamab Vedotin Yields Responses in Gastric/GEJ Cancer With Various HER2 Expression Levels @ascocancer.bsky.social #ASCO25 #esocsm #oncology
www.onclive.com/view/frontli...

The best in #GIonc trials to look for at #ASCO25. 2⃣ plenary talks that will revolutionize #crcsm and #esocsm #stmcsm. Can't wait to take this best of science into the clinic!

@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
@biagioricciutimd.bsky.social

Awareness Efforts Aim to Drive Earlier Esophageal Cancer Detection Amid Rising Incidence Rates Nataliya Uboha, MD, PhD, highlights the importance of standard endoscopic procedures for the early detection of esophageal cancer.

Awareness Efforts Aim to Drive Earlier Esophageal Cancer Detection Amid Rising Incidence Rates
#esocsm #oncology
www.onclive.com/view/awarene...

Program Guide – ASCO Meeting Program Guide

EFS in MATTERHORN: A Ph3 RCT of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin & docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) - @YJanjigianMD et al. #ASCO25 LBA5 meetings.asco.org/abstracts-pr... #NCT04592913 #stcsm #esocsm

SWOG S2303 PARAMUNE

S2303 #PARAMUNE trial tests an anti-VEGFR2 + anti-PD1/L1 combo in patients w #gastric, #GEJ, or esophageal #adenocarcinoma whose dx progressed on (or who were intolerant to) 1st-line chemo + PD1/L1 inhibitor.
swog.org/clinical-tri...
Co-PI: Paul Oberstein, MD
@nyulangone.bsky.social
#gicsm #esocsm

Society of Surgical Oncology Highlights Roswell Park Experts at 2025 Annual Meeting Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.

Society of Surgical Oncology Highlights Roswell Park Experts at 2025 Annual Meeting @aerynkd.bsky.social @roswellpark.bsky.social @socsurgonc.bsky.social #SSO2025 #esocsm #melsm #bcsm #crcsm #oncology
www.onclive.com/view/society...

Study S2303

Study S2303 is for people who are seeking further treatment for advanced #stomach or #esophageal #cancer. It tests adding an #immunotherapy drug (#nivolumab) to usual treatment. SWOG.org/S2303. 1-800-4-CANCER. #esocsm #stcsm #gicsm #gastriccancer

FDA Approval of Tislelizumab Plus Chemo Offers a New Option in Advanced Gastric/GEJ Adenocarcinoma Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab with chemotherapy for advanced gastric or GEJ adenocarcinoma.

FDA Approval of Tislelizumab Plus Chemo Offers a New Option in Advanced Gastric/GEJ Adenocarcinoma @fda.gov #esocsm #oncology
www.onclive.com/view/fda-app...

Camrelizumab/Nab-POF Combo Increases R0 Resection Rates in Gastric/GEJ Cancer Camrelizumab plus Nab-POF was associated with high rates of conversion to R0 resection and high 3-year survival rates in gastric and GEJ adenocarcinoma.

Camrelizumab/Nab-POF Combo Increases R0 Resection Rates in Gastric/GEJ Cancer @ascocancer.bsky.social #GI25 #esocsm #oncology
www.onclive.com/view/camreli...

Neoadjuvant Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC Neoadjuvant sintilimab plus chemoradiotherapy improved pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.

Neoadjuvant Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC @ascocancer.bsky.social #GI25 #esocsm #oncology
www.onclive.com/view/neoadju...

So much excited data shared on Day 1️⃣ of #GI25 from #biomarker 🎯 testing in #esocsm #stcsm to the role of #RT in #esocsm in light 💡 of #ESOPEC. Excited for more great science and discovery on Day 2️⃣!

Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.

Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer @ascocancer.bsky.social #GI25 #esocsm #oncology
www.onclive.com/view/trastuz...

First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.

First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer @mskcancercenter.bsky.social @ascocancer.bsky.social #GI24 #esocsm #oncology
www.onclive.com/view/first-l...

First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.

First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC @ascocancer.bsky.social #GI25 #esocsm #oncology
www.onclive.com/view/first-l...

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INF... In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers improved survival, but limited benefit…

Exciting #GIonc INFINITY ♾ #Ph2 trial

Neoadjuvant #IO in #stcsm #esocsm using #treme + #durva ~60% pCR

12m 🚫🔪#survival ~ 64%.

#Ph3 data needed, but organ preservation possible!

🔗: sciencedirect.com/science/arti...

Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options [Mar 30, 2020] Bitzer et al. @ASCO_pubs ow.ly/MuHP30qAEI0 #PrecisionMedicine #ancsm #crcsm #esocsm #hpbcsm #pancsm #sbcsm #stcsm n=96, Apr 2016 - Feb 2018

Satri-Cel Improves PFS in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer Satri-cel improved PFS vs investigator’s choice of therapy in pretreated CLDN18.2-positive advanced gastric/GEJ cancer.

Satri-Cel Improves PFS in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer #esocsm #oncology
www.onclive.com/view/satri-c...

S2303 PARAMUNE clinical trial

Enrolling: #PARAMUNE @SWOG S2303 ph 2/3 randomized #clinicaltrial of paclitaxel + ramucirumab w/wo nivolumab in patients w advanced MSS, HER2- #gastric, #GEJ, or #esophageal #adenocarcinoma w PD-L1 CPS ≥ 1.
SWOG.org/clinical-trials/S2303
PI: Anwaar Saeed, MD @upmchillmancc.bsky.social #esocsm #gicsm

Let 2025 be the year we find the cure!

#2025CancerCure

Happy New Year To All!

#cansky #oncsky #oncosky #esocsm

FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injecti FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection

#OncSky #MedSky

Another subcutaneous #ImmunoOnc therapy (nivo) now officially in the toolkit 👇

#melsm #lcsm #kcsm #blcsm #gicsm #stcsm #esocsm

www.fda.gov/drugs/resour...

SWOG S2303 study

Do you have #esophageal or #stomach #cancer that has spread or can’t be removed with surgery? If initial treatment didn’t work or stopped working, study S2303 may be an option for you.
SWOG.org/S2303. 1-800-4-CANCER. #esocsm #stcsm #gicsm #PARAMUNE

Gotta get me one of these...

#cansky #oncsky #oncosky #esocsm #FuckCancer

UPDATE: Just got home from my first chemo and radiation treatments. Chemo pump on the left and radiation beast on the right. No adverse side effects so far. 👍

💉☢️

#cansky #oncsky #oncosky #esocsm